<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121200">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02136771</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT no:2009-018125-70</org_study_id>
    <secondary_id>2009-018125-70</secondary_id>
    <nct_id>NCT02136771</nct_id>
  </id_info>
  <brief_title>Styrian Vitamin D Hypertension Trial</brief_title>
  <official_title>Styrian Vitamin D Hypertension Trial: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Systolic Ambulatory Blood Pressure in Vitamin D Deficient Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized, double-blind, placebo-controlled trial we plan to enrol 200 vitamin D
      deficient hypertensive patients. Our main objective is to evaluate whether vitamin D3
      supplementation with 2,800 IU daily for 8 weeks has an effect on 24-hour systolic ambulatory
      blood pressure (ABP) compared to placebo. In addition, we also aim to evaluate whether
      vitamin D3 supplementation alters 24-hour diastolic ABP, pulse wave velocity,
      N-terminal-pro-brain natriuretic peptide (NT-pro-BNP), corrected QT interval (Bazett
      formula), renin, aldosterone, 24-hour urinary albumin excretion, HOMA-IR (HOmeostatic Model
      Assessment: Insulin Resistance), triglycerides and HDL-cholesterol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24-hour systolic ambulatory blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour diastolic ambulatory blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corrected QT interval (Bazett formula)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma renin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma aldosterone concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urinary albumin excretion</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HOMA-IR (HOmeostatic Model Assessment: Insulin Resistance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arterial Hypertension</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oily drops as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks</description>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25-hydroxyvitamin D levels below 30 ng/ml (75 nmol/L)

          -  Arterial hypertension defined according to recent guidelines as an average office
             blood pressure on at least two occasions of systolic ≥ 140 and/or diastolic ≥ 90 mmHg
             or a mean 24-hour ABP of systolic ≥ 125 and/or diastolic ≥ 80, or a home blood
             pressure of systolic ≥ 130 and/or diastolic ≥ 85 or ongoing antihypertensive
             treatment which was initiated due to arterial hypertension

          -  Age of ≥ 18 years

          -  Written informed consent.

        Exclusion Criteria:

          -  Hypercalcemia defined a serum calcium &gt;2.65 mmol/L

          -  Pregnancy or lactating women

          -  Drug intake as part of another clinical study

          -  Acute coronary syndrome or cerebrovascular events in the previous 2 weeks

          -  Glomerular filtration rate (GFR) according to the MDRD formula &lt; 15 ml/min/1.73m²

          -  Systolic 24-hour ABP &gt; 160 mm Hg or &lt; 120 mm Hg

          -  Diastolic 24-hour ABP &gt; 100 mm Hg

          -  Change of antihypertensive treatment (drugs and/or lifestyle) in the previous 4 weeks
             or planned changes of antihypertensive treatment during the study

          -  Any disease with an estimated life expectancy below 1 year

          -  Any clinically significant acute disease requiring drug treatment

          -  Chemotherapy or radiation therapy during the study

          -  Regular intake of more than 880 International Units (IU) vitamin D per day in the
             last four weeks before study entry or during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Pilz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Pilz, MD, PhD</last_name>
    <phone>+43 650 9103667</phone>
    <email>stefan.pilz@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Gaksch, MD</last_name>
    <email>martin.gaksch@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Pilz, MD, PhD</last_name>
      <phone>+43 650 9103667</phone>
      <email>stefan.pilz@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Martin Gaksch, MD</last_name>
      <email>martin.gaksch@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Pilz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Tomaschitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Kienreich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Gaksch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
